Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.63 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 2/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | NPY4R | P50391 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531598 | 1.00 | OPRK1 (0.63) | OPRK1LTA4HMMEERAP2LNPEP | |
| SCHEMBL31138045 | 0.96 | OPRK1 (0.66) | OPRK1LTA4HMMEERAP2LNPEP | |
| SCHEMBL30849690 | 0.96 | OPRK1 (0.66) | OPRK1LTA4HMMEERAP2LNPEP | |
| SCHEMBL30292597 | 0.96 | OPRK1 (0.66) | OPRK1LTA4HMMEERAP2LNPEP | |
| SCHEMBL31571357 | 0.95 | OPRK1 (0.61) | OPRK1LTA4HMMEERAP2LNPEP | |
| SCHEMBL31528272 | 0.95 | OPRK1 (0.61) | OPRK1LTA4HMMEERAP2LNPEP | |
| SCHEMBL30161997 | 0.95 | OPRK1 (0.61) | OPRK1LTA4HMMEERAP2LNPEP | |
| SCHEMBL30957128 | 0.95 | OPRK1 (0.68) | OPRK1LTA4HERAP2LNPEPNPY1R | |
| SCHEMBL30957134 | 0.94 | OPRK1 (0.69) | OPRK1LTA4HERAP2LNPEPNPY1R | |
| SCHEMBL30957126 | 0.94 | OPRK1 (0.69) | OPRK1LTA4HERAP2LNPEPNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605456-B2 | Composition and method for HIP1-targeting inhibitor compounds | UTAH VALLEY UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| US-20230001000-A1 | COMPOSITION AND METHOD FOR HIP1-TARGETING INHIBITOR COMPOUNDS | UTAH VALLEY UNIVERSITY | 2023-01-05 | — | — | US | claimed |
| US-12605456-B2 | Composition and method for HIP1-targeting inhibitor compounds | UTAH VALLEY UNIVERSITY (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250237649-A1 | COMPOSITIONS AND METHODS FOR HIP1-TARGETING INHIBITOR COMPOUNDS | UTAH VALLEY UNIVERSITY | 2025-07-24 | — | — | US | disclosed |
| US-20230001000-A1 | COMPOSITION AND METHOD FOR HIP1-TARGETING INHIBITOR COMPOUNDS | UTAH VALLEY UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605456-B2 | Composition and method for HIP1-targeting inhibitor compounds | CHAMP1, WHR1, OTUB1 | OPRK1 3957/4885LTA4H 1321/4885MME 1388/4885 |
| US-20230001000-A1 | COMPOSITION AND METHOD FOR HIP1-TARGETING INHIBITOR COMPOUNDS | HIPK1, WHR1, HIPK3 | OPRK1 4443/4885LTA4H 4124/4885MME 2035/4885 |
| US-20250237649-A1 | COMPOSITIONS AND METHODS FOR HIP1-TARGETING INHIBITOR COMPOUNDS | HIPK1, HIPK3, HIPK2 | OPRK1 3710/4885LTA4H 2585/4885MME 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.